Targeting the stratum corneum is key.1
Spinosad, the active compound in Spinosad Topical Suspension 0.9%, represents an entirely novel MOA for scabicides that targets mites right where they live, eat, and breed, while not entering systemic circulation.1,2Learn More
The Spinosad Topical Suspension 0.9% formulation was designed to drive spinosad to the site of the infestation.1
When applied on the outer layer of the epidermis,:
- Spinosad Topical Suspension 0.9% liquefies at body temperature1
- The active compound (spinosad) sloughs off through a natural process of non-pathologic desquamation (over approximately 14 days)3
Spinosad Topical Suspension 0.9% MOA defines targeted topical therapy:1
- Spinosad, the active compound, does not penetrate into the dermis or enter into the systemic circulation, and is therefore not absorbed systemically in the lipids of major organs, including the brain, heart, lungs, kidneys, and liver
- There is no prolonged prevalence of the the active compound, spinosad
- There are no concerns regarding the speed of drug metabolism for the active compound, spinosad
- Data on file, ParaPRO, LLC.
- Spinosad Topical Suspension Prescribing Information.
- Jackson SM, et. al: Pathobiology of the stratum corneum. West J Med 1993 Mar; 158:279-285).